Huang Xuan, Tang Jing
Department of Pharmacy, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, People's Republic of China.
Onco Targets Ther. 2020 Oct 22;13:10721-10727. doi: 10.2147/OTT.S269983. eCollection 2020.
Multidrug resistance is the main cause of chemotherapy failure and death in patients with advanced ovarian cancer. Drug resistance is a problem that must be solved to improve the survival rate of patients with advanced ovarian cancer. The RNA-binding protein La and the La-related protein family are highly expressed in various malignant tumors, including ovarian cancer. This article reviews the mechanisms of La protein in tumorigenesis, development, and drug resistance. High La protein expression in tumor cells promotes tumor proliferation, invasion, and migration; disrupts cell cycle; and inhibits tumor cell apoptosis caused by chemotherapeutic drugs through various pathways, resulting in chemotherapy resistance in ovarian cancer. Further study of the role of La protein in ovarian cancer multidrug resistance may be conducive to the development of human La protein-specific inhibitors that suppress ovarian cancer drug resistance.
多药耐药是晚期卵巢癌患者化疗失败和死亡的主要原因。耐药性是提高晚期卵巢癌患者生存率必须解决的问题。RNA结合蛋白La及La相关蛋白家族在包括卵巢癌在内的多种恶性肿瘤中高表达。本文综述了La蛋白在肿瘤发生、发展及耐药中的作用机制。肿瘤细胞中高表达的La蛋白通过多种途径促进肿瘤增殖、侵袭和迁移;扰乱细胞周期;抑制化疗药物引起的肿瘤细胞凋亡,导致卵巢癌化疗耐药。进一步研究La蛋白在卵巢癌多药耐药中的作用可能有助于开发抑制卵巢癌耐药的人La蛋白特异性抑制剂。